The transcriptional profile of circulating myeloid derived suppressor cells correlates with tumor development and progression in mouse

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Genes and Immunity

• Publication date

  2019-03-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41435-019-0062-3PMID 30880333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myeloid-derived suppressor cells coming of age

  2018cited by this paper
• Diagnostic value of peripheral blood immune profiling in colorectal cancer

  2018cited by this paper
• Abstract BS1-2: Myeloid-derived suppressor cells: many facets of regulation of tumor progression

  2018cited by this paper
• Tumor-associated myeloid cells as guiding forces of cancer cell stemness

  2017cited by this paper
• CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development.

  2017cited by this paper
• The ratio of HLA-DR and VNN2+ expression on CD14+ myeloid derived suppressor cells can distinguish glioblastoma from radiation necrosis patients

  2017cited by this paper
• Myeloid-Derived Suppressor Cells

  2017cited by this paper
• Increased Percentage of mo-MDSCs in Human Peripheral Blood May Be a Potential Indicator in the Diagnosis of Breast Cancer

  2017cited by this paper
• Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer

  2017cited by this paper
• The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

  2016cited by this paper
• Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)

  2016cited by this paper
• The clinical and prognostic significance of CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy

  2016cited by this paper
• Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients

  2016cited by this paper
• Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent

  2016cited by this paper
• Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer

  2015cited by this paper
• Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC

  2015cited by this paper
• Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

  2014cited by this paper
• Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer

  2014cited by this paper
• HTSeq—a Python framework to work with high-throughput sequencing data

  2014cited by this paper
• Next maSigPro: updating maSigPro bioconductor package for RNA-seq time series

  2014cited by this paper
• Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients

  2014cited by this paper
• Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.

  2014cited by this paper
• Count-based differential expression analysis of RNA sequencing data using R and Bioconductor

  2013cited by this paper
• TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

  2013cited by this paper
• Unique expression patterns associated with preferential recruitment of immature myeloid cells into angiogenic versus dormant tumors

  2013cited by this paper
• Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients

  2013cited by this paper
• Complement inhibition in cancer therapy.

  2013cited by this paper
• Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells

  2013cited by this paper
• Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma

  2013cited by this paper
• Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

  2013cited by this paper
• Recruitment of a myeloid cell subset (CD11b/Gr1mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis *

  2013cited by this paper
• Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma.

  2012cited by this paper
• Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

  2011cited by this paper
• Immature myeloid cells derived from mouse placentas and malignant tumors demonstrate similar proangiogenic transcriptional signatures.

  2011cited by this paper
• S100A8/A9 Activate Key Genes and Pathways in Colon Tumor Progression

  2011cited by this paper
• Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung.

  2010cited by this paper
• Regional Control of Tumor Growth

  2010cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

  2008cited by this paper
• Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells.

  2008cited by this paper
• Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

  2007cited by this paper
• Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models.

  2006cited by this paper
• Cancer without disease

  2004cited by this paper
• Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.

  2004cited by this paper
• Gene Expression Omnibus: NCBI gene expression and hybridization array data repository

  2002cited by this paper
• Angiogenic factors.

  1987cited by this paper
• TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION

  1972cited by this paper

• Role of vascular endothelium and exosomes in cancer progression and therapy (Review)

  2024cites this paper
• The immune system contributes to the effectiveness of vaccine therapy in patients with metastatic melanoma

  2023cites this paper
• CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor

  2022cites this paper
• Infection-Derived Monocytic MDSCs Require TGF-β to Suppress Filarial-Specific IFN-γ But Not IL-13 Release by Filarial-Specific CD4+ T Cells In Vitro

  2022cites this paper
• Annexin A1 as a Regulator of Immune Response in Cancer

  2021cites this paper
• High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling

  2020cites this paper
• Endothelial-to-Mesenchymal Transition (EndoMT): Roles in Tumorigenesis, Metastatic Extravasation and Therapy Resistance

  2019cites this paper